Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 278.75 GBp
Change Today -3.25 / -1.15%
Volume 52.5K
SKP On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 11:35 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

skyepharma plc (SKP) Snapshot

Open
288.00 GBp
Previous Close
282.00 GBp
Day High
288.00 GBp
Day Low
273.25 GBp
52 Week High
12/1/14 - 377.50 GBp
52 Week Low
08/1/14 - 229.50 GBp
Market Cap
292.2M
Average Volume 10 Days
53.0K
EPS TTM
-0.20 GBp
Shares Outstanding
104.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SKYEPHARMA PLC (SKP)

Related News

No related news articles were found.

skyepharma plc (SKP) Related Businessweek News

No Related Businessweek News Found

skyepharma plc (SKP) Details

Skyepharma PLC develops and sells oral and inhalation pharmaceutical products. The company’s inhalation products include flutiform, a multi-dose pressurized metered dose inhaler for the treatment of bronchial asthma; Anoro Ellipta and Incruse Ellipta multi-dose dry powder inhalers for the treatment of chronic obstructive pulmonary disease (COPD); and Relvar Ellipta/Breo Ellipta multi-dose dry powder inhaler for the treatment of asthma and COPD. It also offers Solaraze, a topical gel treatment for actinic keratosis; and Exparel, a bupivacaine injectable product for post-surgical pain management. The company’s oral drug delivery products comprise Paxil CR, an anti-depressant; Sular, a calcium channel blocker antihypertensive agent; Xatral OD, a selective alpha blocker for the treatment of BPH (urinary symptoms); Requip for Parkinson’s disease; Diclofenacratiopharm uno, a dual release diclofenac sodium formulation for pain/inflammation; and ZYFLO CR, an extended-release formulation of the oral asthma drug zileuton. Its oral drug delivery products also comprise Madopar DR, an oral treatment for Parkinson’s disease; Lodotra, a night-time release formulation of low dose prednisone for the treatment of morning stiffness associated with rheumatoid arthritis; Triglide, an oral treatment for elevated blood lipid disorders; and Coruno for the oral treatment of chronic angina pectoris. The company has partnerships with various companies, including GlaxoSmithKline, Sanofi, Mundipharma, and Kyorin worldwide. Skyepharma PLC was founded in 1910 and is headquartered in London, the United Kingdom.

92 Employees
Last Reported Date: 04/10/15
Founded in 1910

skyepharma plc (SKP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 567.0K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 74.0K GBP
Compensation as of Fiscal Year 2013.

skyepharma plc (SKP) Key Developments

Skyepharma PLC Presents at BIO International Convention 2015, Jun-17-2015 04:00 PM

Skyepharma PLC Presents at BIO International Convention 2015, Jun-17-2015 04:00 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.

Skyepharma PLC Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:00 AM

Skyepharma PLC Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Peter William Grant, Chief Executive Officer and Executive Director.

Skyepharma Seeks Acquisitions

Skyepharma PLC (LSE:SKP) is seeking acquisitions. Barclays has provided Skyepharma a £25 million revolving credit facility. The funding from Barclays will be used for general corporate purposes including acquisitions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SKP:LN 278.75 GBp -3.25

SKP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $7.65 USD -0.23
Onxeo SA €4.96 EUR +0.02
Pfizer Ltd/India 2,122 INR -12.90
Veloxis Pharmaceuticals A/S kr1.06 DKK -0.02
XenoPort Inc $7.14 USD +0.02
View Industry Companies
 

Industry Analysis

SKP

Industry Average

Valuation SKP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book 10.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SKYEPHARMA PLC, please visit www.skyepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.